Cover Image

Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)

Stefano Fagiuoli,1 Pierluigi Toniutto,2 Nicola Coppola,3 Domenica Daniela Ancona,4 Margherita Andretta,5 Fausto Bartolini,6 Fulvio Ferrante,7 Alessandro Lupi,8 Stefano Palcic,9 Francesca Vittoria Rizzi,10 Davide Re,11 Gema Alvarez Nieto,12 Candido Hernandez,13 Francesca Frigerio,14 Valentina Perrone...

Full description

Saved in:

Bibliographic Details
Main Authors:	Fagiuoli S (Author), Toniutto P (Author), Coppola N (Author), Ancona DD (Author), Andretta M (Author), Bartolini F (Author), Ferrante F (Author), Lupi A (Author), Palcic S (Author), Rizzi FV (Author), Re D (Author), Alvarez Nieto G (Author), Hernandez C (Author), Frigerio F (Author), Perrone V (Author), Degli Esposti L (Author), Mangia A (Author)
Format:	Book
Published:	Dove Medical Press, 2023-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy
by: Degli Esposti L, et al.
Published: (2022)

Evaluation of the Therapeutic Pattern and Pharmaco-Utilization in Hypercholesterolemic Patients Treated with Statins: A Retrospective Study on Italian Real-World Data
by: Perrone V, et al.
Published: (2022)

Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**
by: Roberto Focaccia, et al.
Published: (2015)

Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine
by: Thu-Lan T. Luong, et al.
Published: (2022)

Drug adherence to olmesartan/amlodipine fixed combination in an Italian clinical practice setting
by: Degli Esposti L, et al.
Published: (2014)

Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator
by: Peter J. Kilford, et al.
Published: (2022)

Analysis of Patients with Focal Epilepsy and Drug-Resistant Epilepsy in Italy: Evaluation of Their Characteristics, Therapeutic Pathway and the Consumption of Healthcare Resources
by: Perrone V, et al.
Published: (2022)

Access to free DAAs for people who inject drugs: is it sufficient to increase the update of HCV treatment by PWIDs?
by: Maka Gogia, et al.
Published: (2018)

Analysis of Patients’ Characteristics and Treatment Profile of People Who Use Drugs (PWUDs) with and without a Co-Diagnosis of Viral Hepatitis C: A Real-World Retrospective Italian Analysis
by: Nava FA, et al.
Published: (2023)

Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study
by: Degli Esposti L, et al.
Published: (2014)

On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era
by: Dana Busschots, et al.
Published: (2021)

Anti-HCV DAA are needed whatever liver fibrosis is. The cons
by: Pablo Barreiro
Published: (2016)

Anti-HCV DAA are needed whatever liver fibrosis is. The pros
by: Albert Tran
Published: (2016)

Treatment Pattern Analysis and Health-care Resource Consumption on Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Biological Drugs in a Northern Italian Region
by: Perrone V, et al.
Published: (2020)

The effect of APN, hs-CRP and APN/hs-CRP in periodontitis with DAA
by: Rui Cheng, et al.
Published: (2023)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
by: Fabrizio Fabrizi, et al.
Published: (2021)

P62 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1-6 patients without cirrhosis
by: Massimo Puoti, et al.
Published: (2017)

O9 Progress towards elimination: rapid uptake of HCV treatment among people who inject drugs following broad access to DAA therapies
by: J. Iversen, et al.
Published: (2017)

Virological impact of HCV elimination with DAAs in the HIV reservoir in HIV/HCV patients
by: M. Coiras, et al.
Published: (2019)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
by: Hrvoje Roguljic, et al.
Published: (2021)

Hepatitis C virus infection: Epidemiology in Egypt, Pathophysiology and DAAs-based therapy
by: Heba Elbadawy, et al.
Published: (2021)

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
by: Degli Esposti L, et al.
Published: (2014)

Epidemiology, Patients' Journey and Healthcare Costs in Early-Stage Non-Small-Cell Lung Carcinoma: A Real-World Evidence Analysis in Italy
by: Diego Luigi Cortinovis, et al.
Published: (2023)

IMPLEMENTASI KONSEP TAâ€™DÄªB DALAM PENDIDIKAN ISLAM UNTUK MEWUJUDKAN SISWA BERKARAKTER
by: Maria Ulfah
Published: (2015)

O11 Hepatitis C: stigma indicators and patient reported outcome measures for DAA treatment
by: C. Treloar, et al.
Published: (2017)

Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population
by: Perrone V, et al.
Published: (2023)

Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases
by: Degli Esposti L, et al.
Published: (2013)

IMPLEMENTASI KONSEP TAâ€™DÄªB DALAM PENDIDIKAN ISLAM UNTUK MEWUJUDKAN SISWA YANG BERKARAKTER
by: Maria Ulfah
Published: (2011)

P66 A year of living safely: 12 months of DAA treatment in Canberra's prison system
by: J. Wenke, et al.
Published: (2017)

Epidemiological and economic evaluations according to DAA treatment access: an interim evaluation based on PITER cohort data
by: Stefano Vella, et al.
Published: (2018)

Analysis of disease patterns and cost of treatments for prevention of deep venous thrombosis after total knee or hip replacement: results from the Practice Analysis of THromboprophylaxis after Orthopaedic Surgery (PATHOS) study
by: Degli Esposti L, et al.
Published: (2012)

O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued
by: A.J. Kwon, et al.
Published: (2017)

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy
by: Degli Esposti L, et al.
Published: (2016)

P28 Queensland injectors health network (QuIHN) treatment management program (TMP): hepatitis C virus (HCV) direct acting antivirals (DAA) full access for people who inject drugs
by: R. Kavanagh, et al.
Published: (2017)

P22 'No closed door' to HCV treatment in the era of fully funded DAAs: access to a peer navigator is essential
by: M.E. Harrod, et al.
Published: (2017)

Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia
by: Almoutaz Hashim, et al.
Published: (2020)

P38 Hepatitis NSW's specialised counselling service: professional support for people undertaking DAA treatment for viral hepatitis C
by: L. Pesa, et al.
Published: (2017)

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.
by: Kamila Abram, et al.
Published: (2023)

Triangulating evidence on the role of perceived versus objective experiences of childhood adversity in psychopathology
by: Jessie R. Baldwin, et al.
Published: (2021)

METHODICAL PREPARATION OF STUDENTS FACULTIES OF ARTS PEDAGOGICAL UNIVERSITIES
by: F.V. Kryvozub
Published: (2004)